CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

NCT05617625 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

50

Enrollment

OTHER

Sponsor class

Stopped The study has been put on hold while pending CMS approval

Conditions

Myelodysplastic Syndromes
Graft Vs Host Disease
Graft-versus-host-disease

Interventions

DRUG: Busulfan
DRUG: Melphalan
DRUG: Fludarabine
DEVICE: CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)

Sponsor

Guenther Koehne